Tumour marker CA 50 levels compared to signs and symptoms in the diagnosis of pancreatic cancer

European Journal of Surgical Oncology

Volumn 23, Issue 2, 1997, Pages 151-156

  Pålsson, Birger ^a   Masson, Parvesh ^b   Andrén Sandberg, Åke ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

CA 50; Exocrine pancreatic cancer; Tumour marker; Tumour associated antigens

Indexed keywords

CA 50 ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC PANCREATITIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DIGESTIVE SYSTEM CANCER; FEMALE; HUMAN; JAUNDICE; MAJOR CLINICAL STUDY; MALABSORPTION; MALE; PAIN; PANCREAS CANCER; PREDICTION; PRIORITY JOURNAL; SYMPTOM; WEIGHT REDUCTION;

EID: 0030943078     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0748-7983(97)80011-X     Document Type: Article

References (24)

1. Go VLW, Taylor WF, DiMagno EP. Efforts at early diagnosis of pancreatic cancer: the Mayo Experience. Cancer 1981; 47: 1698-703.
2. Moossa AR. Pancreatic cancer. Approach to diagnosis, selection for surgery and choice of operation. Cancer 1982; 50: 2689-98.
3. Kaiser MH, Barkin JS, MacIntyre IM. Pancreatic cancer. Assessment of prognosis by clinical presentation. Cancer 1985; 56: 397-402.
4. Cubilla AL, Fitzgerald PJ. Tumors of the exocrine pancreas. In: Atlas of Tumor Pathology, 2nd series, fasc. 19. Armed Forces Institute of Pathology: Washington, DC, 1984: 1-4, 111-54.
5. International Union Against Cancer Report. Workshop on immunodiagnosis. Cancer Res 1986; 46: 3744-6.
6. Kuusela P, Haglund C, Roberts PJ, Jalanko H. Comparison of CA-50, a new tumour marker, with carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in patients with gastrointestinal diseases. Br J Cancer 1987; 55: 673-6.
7. Paganuzzi M, Onetto M, Marroni P, Barone D, Conio M, Aste H, Pugliese V. CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases. Cancer 1988; 61: 2100-8.
8. Haglund C, Kuusela P, Jalanko H, Roberts P. Serum CA 50 as a tumor marker in pancreatic cancer: a comparison with CA 19-9. Int J Cancer 1987; 39: 477-81.
9. Masson P, Pålsson B, Andrén-Sandberg Å. Evaluation of CEA, CA 19-9, CA-50, CA-195 and TATI with special reference to pancreatic disorders. Im J Pancreatol 1991; 8: 333-44.
10. Benini L, Cavallini G, Zordan D, et al. A clinical evaluation of monoclonal (CA 19-9, CA 50, CA 12-5) and polyclonal (CEA, TPA) antibody-defined antigens for the diagnosis of pancreatic cancer. Pancreas 1988; 3: 61-6.
11. Blind PJ, Dahlgren ST. Serum levels of the carbohydrate antigen CA-50 in pancreatic disease. Acta Chir Scand 1986; 153: 45-9.
12. Haglund C, Roberts PJ, Jalanko H, Kuusela P. Tumour markers CA 19-9 and CA 50 in digestive tract malignancies. Scand J Gastroenterol 1992; 27: 169-74.
13. Habib NA, Hershman MJ, Haberland F, Papp L, Wood CB, Williamson RCN. The use of CA-50 radioimmunoassay in differentiating benign and malignant pancreatic disease. Br J Cancer 1986; 53: 697-9.
14. Kobayashi T, Kawa S, Tokoo M, et al. Comparative study of CA-50 (Time-Resolved Fluoroimmunoassay), Span-1, and CA 19-9 in the diagnosis of pancreatic cancer. Scand J Gastroenterol 1991; 26: 787-97.
15. Lindholm L, Holmgren J, Svennerholm L, et al. Monoclonal antibodies against gastrointestinal tumour-associated antigens isolated as monosialogangliosides. Int Archs Allergy Appl Immun 1983; 71: 178-81.
16. Månsson JE, Fredman P, Nilsson O, Lindholm L, Holmgren J, Svennerholm L. Chemical structure of carcinoma ganglioside antigens defined by monoclonal antibody C-50 and some allied gangliosides of human pancreatic adenocarcinoma. Biochim Biophys Acta 1985; 834: 110-7.
17. Nilsson O, Månsson JE, Lindholm L, Holmgren J, Svennerholm L. Sialosyllacto-tetraosyl ceramide, a novel ganglioside antigen detected in human carcinomas by monoclonal antibody. FEBS Lett 1985; 182: 398-402.
18. Koprowski H, Herlyn M, Steplewski Z, et al. Colorectal carcinoma antigens detected by hybridoma antibodies. Somat Cell Genet 1979; 5: 957-72.
19. Magnani JL, Nilsson B, Brockhaus M, et al. A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. J Biol Chem 1982; 257: 14365-9.
20. Masson P, Pålsson B, Andrén-Sandberg Å. CA-50 in patients with different pancreatic diseases - an evaluation of three different laboratory techniques. Scand J Clin Lab Invest 1988; 48: 751-5.
21. Kuusela P, Haglund C, Roberts PJ. Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases. Br J Cancer 1991; 63: 636-40.
22. Nilsson O, Johansson C, Glimelius B, Persson B, Nörgaard-Pedersen B, Andrén-Sandberg Å, Lindholm L. Sensitivity and specificity of CA 242 in gastrointestinal cancer. A comparison with CEA, CA 50 and CA 19-9. Br J Cancer 1991; 65: 215-21.
23. Pålsson B, Masson P, Andrén-Sandberg Å. The influence of cholestasis on CA 50 and CA 242 in pancreatic cancer and benign biliopancreatic diseases. Scand J Gastroenterol 1993; 28: 981-7.
24. Bonfrer JMG. Working group on tumour marker criteria (WGTMC). Tumor Biol 1990; 11: 287-8.